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Abstract
Growth factor-induced receptor dimerization and cross-phosphorylation are hallmarks of signal transduction via
receptor tyrosine kinases (RTKs). G protein-coupled receptors (GPCRs) can activate RTKs through a process known
as transactivation. The prototypical model of RTK transactivation involves ligand-mediated RTK dimerization and
cross-phosphorylation. Here, we show that the platelet-derived growth factor receptor b (PDGFRb) transactivation
by the dopamine receptor D4 (DRD4) is not dependent on ligands for PDGFRb. Furthermore, when PDGFRb dimer-
ization is inhibited and receptor phosphorylation is suppressed to near basal levels, the receptor maintains its
ability to be transactivated and is still effective in signaling to ERK1/2. Hence, the DRD4-PDGFRb-ERK1/2 pathway
can occur independently of a PDGF-like ligand, PDGFRb cross-phosphorylation and dimerization, which is distinct
from other known forms of transactivation of RTKs by GPCRs.
Introduction
Receptor tyrosine kinases (RTKs) consist of a large
family of receptors whose members serve a wide range
of physiological functions including growth, differentia-
tion and synaptic modulation. The members of this
receptor family generally feature an extracellular ligand-
binding domain, linked by a transmembrane domain to
an intracellular tyrosine kinase domain, as well as sev-
eral SH2 domain-binding sites. It is generally believed
that the mechanism of RTK signaling involves ligand-
induced dimerization of the RTK followed by cross-
phosphorylation of the tyrosine-containing motifs, which
subsequently interact with SH2 domain-containing
molecules such as the PI3-kinase, PLC-g,S r c ,S H P - 2 ,
Grb-2 and RasGAP, to effect downstream responses [1].
The large family of G protein-coupled receptors
(GPCRs) activates heterotrimeric G proteins and can
mediate several cellular processes, including prolifera-
tion, differentiation and survival. The ERK1/2 signaling
pathway is among the major effector pathways through
which GPCRs mediate their responses [2,3]. Many
GPCRs engage in ERK1/2 signaling via the activation of
RTKs, in a process known as transactivation [2-4].
GPCRs such as the dopamine receptors D4 (DRD4) and
D2 (DRD2) [5-7], b2 adrenergic receptor [8], M1 mus-
carinic receptor [9], angiotensin II receptor [10], lyso-
phosphatidic acid (LPA) receptor [11], ET1 receptor
[12] and thrombin receptor [12] have been shown to
transactivate either the epidermal growth factor receptor
(EGFR) or the platelet-derived growth factor receptor b
(PDGFRb). Upon GPCR stimulation, these transacti-
vated RTKs exhibit increased tyrosine phosphorylation,
as seen similarly following growth factor-induced activa-
tion. The transactivation of EGFR by the b2 adrenergic
receptor is also characterized by increased dimerization
of EGFR [8]. In many cases, the transactivation of EGFR
is mediated in either a paracrine or autocrine fashion by
the metalloproteinase-dependent release of heparin-
binding (HB)-EGF. Hence, the mechanism of EGFR acti-
vation by GPCRs is similar to that by its own ligand.
Previous work from our laboratory and our collabora-
tors has demonstrated the DRD4-mediated transactiva-
tion of PDGFRb in hippocampal neurons [13] as well as
in DRD4-expressing CHO-K1 cells [5]. Despite specula-
tion of a similar mechanism to EGFR transactivation,
the mechanism of PDGFRb transactivation is not clear.
The present study aims to investigate the mechanism by
which the PDGFRb is transactivated via DRD4 by exam-
ining the roles of a paracrine or autocrine mediator,
PDGFRb cross-phosphorylation and PDGFRb dimeriza-
tion in this process.
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Reagents and antibodies
Recombinant human PDGF-BB was purchased from
R&D Systems (Minneapolis, MN, USA). Dopamine,
wortmannin and tyrphostin A9 were obtained from
Sigma-RBI (St. Louis, MO, USA). AG1295 and GM6001
were purchased from Calbiochem (San Diego, CA,
USA). CRM197 was purchased from List Biochemical
Laboratories (Campbell, CA, USA). Antibodies raised
against b-tubulin, phospho-Shc and the carboxy term-
inal region of human PDGFRb from residues 958 to
1106 were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies raised against the
extracellular domain of human PDGFRb were obtained
in a biotinylated form from R&D Systems (Minneapolis,
MN, USA). Antibodies specific to different phosphoryla-
tion sites on PDGFRb were obtained from two different
sources. Anti-phospho-PDGFRb-Tyr716 was from
Upstate Biotechnology (Charlottesville, VA, USA), and
phosphospecific PDGFRb antibodies directed against
Tyr740, 751, 857, and 1021 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). General
phosphotyrosine antibodies in an unconjugated form
(4G10) and in a horseradish peroxidase-conjugated form
(PY20) were purchased from Upstate Biotechnology
(Charlottesville, VA, USA) and BD Transduction
Laboratories (Franklin Lakes, NJ, USA), respectively.
Antibodies to ERK1/2 and phospho-ERK1/2 (Thr202/
Tyr204) (E10) were obtained from Cell Signaling Tech-
nology (Beverly, MA, USA). Anti-FLAG antibody was
purchased from Sigma (St. Louis, MO, USA). Peroxi-
dase-conjugated antibodies to mouse and rabbit IgG
were purchased from Sigma (St. Louis, MO, USA) and
Cell Signaling Technology (Beverly, MA, USA), respec-
tively. Lipofectamine, G418, zeocin, fetal bovine serum,
and horse serum were purchased from Invitrogen Life
Technologies (Burlington, ON, Canada). Media used in
cell cultures were obtained from either Invitrogen Life
Technologies (Burlington, ON, Canada) or Sigma (St.
Louis, MO, USA).
Plasmids
Expression vectors for epitope-tagged DRD4 and
PDGFRb h a v eb e e nd e s c r i b e db yu sp r e v i o u s l y[ 5 ] .T h e
plasmid encoding the FLAG-tagged human PDGFRb
w a sag i f tf r o mD r .N .J .F r e e d m a n( D u k eU n i v e r s i t y ,
NC, USA) [14]. All plasmids were subcloned into either
pcDNA3 or pcDNA3.1 vectors (Invitrogen) containing
antibiotic resistance genes for selection with either G418
or zeocin, respectively. A carboxyl-terminal truncated
human PDGFRb (C-truncPDGFRb) was constructed, as
reported by Ueno et al. [15] for the mouse PDGFRb,b y
truncating the wild-type human receptor after amino
acid residue 615 [16]. The insert coding for this trun-
cated receptor was cloned into the EcoRI and XbaI
restriction endonuclease sites in pcDNA3.1-Myc-His-A
vector (Invitrogen) for C-terminal tagging of the protein
and expression in mammalianc e l l s .T oc o n s t r u c tt h e
GST-Ig4b, the fourth immunoglobulin domain of the
mouse PDGFRb was taken as the region from amino
acid residues 314 to 413 [16], based on an alignment
with the region reported for the human receptor [17],
and cloned into the BamHI and EcoRI restriction endo-
nuclease sites in pGEX-3X (Amersham, Little Chalfont,
Buckinghamshire, UK). The sequences of the inserts in
all the plasmids used in the present study were con-
firmed by automatic sequencing (CEQ 2000XL, Beck-
man Coulter).
Cell cultures and transfection
CHO-K1 cells were maintained in a-MEM supplemen-
ted with 2.5% fetal bovine serum and 2.5% horse serum
[5]. CHO-K1 cells stably expressing HA-DRD4 (CHO/
DRD4) or FLAG-PDGFRb (CHO/PR) alone were main-
tained in the serum-containing medium supplemented
with 500 μg/mL G418, and CHO-K1 cells stably expres-
sing both the HA-DRD4 and FLAG-PDGFRb (CHO/
DRD4-PR) were maintained in serum-containing med-
ium supplemented with both 500 μg/mL G418 and 200
μg/mL zeocin.
For assays on cell lines not subject to further transfec-
tion, the cells were seeded and grown to 70-90% con-
fluency prior to serum-deprivation. Transfection was
performed on 100 mm plates with a mixture containing
36 μL lipofectamine and 8 μg DNA. The mixture was
prepared in 0.6 mL OPTI-MEM (Invitrogen) and incu-
bated for 45 minutes at room temperature before
another 6.4 mL of OPTI-MEM was added to yield the
final transfection mixture. One day prior to transfection,
cells were seeded at a density of 2 × 10
6 cells per 100
mm. Transfection was allowed to take place for 5 h,
after which time an equal volume of 2 × serum-contain-
ing a-MEM was added. On the following day, cells
intended for assays were replated at 60-80% confluency
or at 0.4-1% for establishing stable cell lines. To estab-
lish cell lines expressing the desired constructs stably,
the transfected cells were allowed to form isolated colo-
nies. Positive colonies were selected by their resistance
to G418 or zeocin. The expression of the desired pro-
teins in the isolated colonies was determined by western
blotting.
siRNA
The two double-stranded RNA constructs containing
the PDGFRb-specific sequences used were PDGFRb
silencer 1: (sense) 5′-GCAUCUUCAACAGCCUCUAtt-
3′ and (antisense) 5′-CAGAGGCUGUUGAAGAUGCtt-
3′ and PDGFRb silencer 2: (sense) 5′-GUGGACUCC-
GAUACUUACUtt-3′ and (antisense) 5′-AGUAA-
GUAUCGGAGUCCACtt-3′. These oligonucleotides, as
well as the scrambled siRNA (cat. # 4611), were
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PDGFRb expression, CHO/DRD4 cells were transfected
with 30 or 100 nM dsRNA using siPORT transfection
reagent (Ambion, Austin, TX) according to the manu-
facturer’s instructions. After 72 h, the cells were used
for pharmacological manipulation and harvested for
western analysis.
GST-Ig4 fusion protein blocking experiments
GST and GST-Ig4b fusion proteins were expressed in
BL21 E. coli. Purification from bacterial lysates was car-
ried out according to the manufacturer’sp r o t o c o l
(Amersham). Elution from glutathione-Sepharose beads
(Amersham) was performed as described by Omura et
al. [18]. For cell assays, the purified proteins were
applied at 4 μg/mL and pre-incubated for 20 minutes at
37°C prior to agonist stimulation.
Cell assays
CHO-K1 cells were serum-deprived for 24 h prior to
assays with either PDGF-BB (10 ng/mL) or dopamine (1
μM) for 5 minutes. In experiments using kinase inhibi-
tors, the cells were pre-incubated with the inhibitor or
the appropriate vehicle control solution for 1 h before
stimulation with the agonists. Following incubation, cells
were chilled immediately on ice and washed two times
with ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 5.4 mM
Na2HPO4, 1.8 mM KH2PO4, pH 7.4). Cells were scraped
on ice in RIPA buffer supplemented with protease and
phosphatase inhibitors (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 0.5%
deoxycholate, 0.1% SDS, 5 μg/mL aprotinin, 2 μg/mL
leupeptin, 1 μg/mL pepstatin A, 1 mM PMSF, 1 mM
Na3VO4, 2.5 mM pyrophosphate·Na, 1 mM b-glycero-
phosphate). Sodium orthovanadate was activated using
the method described by Gordon et al. [19]. Lysis was
performed at 4°C for 1 h with continuous shaking. An
equal amount of protein was taken from each sample
for further analysis by immunoprecipitation and/or wes-
tern blotting.
Immunoprecipitation and immunoblotting
Immunoprecipitation was performed by mixing 1-2 μg
antibody with RIPA cell lysates. The mixture was shaken
for a minimum of 1 h to overnight at 4°C. After addi-
tion of 25 μL Protein A/G Plus beads (Santa Cruz), the
incubation was allowed to continue for a total of 17-19
h at 4°C. Immunoprecipitates were collected by centrifu-
gation after washing three times with the NP-40 buffer
(50 mM HEPES, 250 mM NaCl, 0.5% NP-40, 10% gly-
cerol, 2 mM EGTA, 5 μg/mL aprotinin, 2 μg/mL leu-
peptin, 1 μg/mL pepstatin A, 1 mM PMSF, 1 mM
Na3VO4, 2.5 mM pyrophosphate·Na, 1 mM b-
glycerophosphate).
Immunoblotting with phosphotyrosine antibody was
performed with a procedure adapted from Klapper et al.
[20] to reduce background staining. Briefly, the blocking
of non-specific binding on PVDF membranes and the
dilution of antibodies was performed in blocking buffer
A (10 mM Tris-HCl, 154 mM NaCl, 2.5 mM MgCl2,3 %
BSA, pH 7.4). Following incubation with antibodies, the
membranes were washed twice with the buffer B (10
mM Tris-HCl, 0.9% NaCl, 0.05% MgCl2,p H7 . 4 ) ,o n c e
with blocking buffer B supplemented with 0.3% Tween
2 0 ,a n dt w i c em o r ew i t ht h eblocking buffer B. Each
wash was carried out for 5 minutes on a rocking plat-
form. Blocking buffer C (10 mM Tris-HCl, 150 mM
N a C l ,3 %B S A ,0 . 1 %T w e e n2 0 ,p H7 . 4 )w a su s e di na l l
associated procedures for immunoblotting with biotiny-
lated antibodies, and blotto (10 mM Tris-HCl, 150 mM
NaCl, 5% non-fat dry milk, 0.1% Tween 20, pH 7.4) was
used for immunoblotting with other antibodies. Work-
ing dilutions of antibodies were prepared as recom-
mended by manufacturers.
Data Analysis
Densitometry was performed on Storm 860 phosphori-
mager (Amersham) with ECL Plus chemiluminescent
reagent (Amersham). Quantitation was done using Ima-
geQuant 5.0 software (Molecular Dynamics). Curve fit-
ting was performed in GraphPad Prism 3.0 (San Diego,
CA, USA). Details pertaining to specific experiments are
provided in the legends to the figures.
Results
Growth factor-activated PDGFRb results in receptor
cross-phosphorylation of tyrosine residues. We have
previously shown that, in CHO-K1 cells stably expres-
sing DRD4 (CHO/DRD4), dopamine stimulates the
phosphorylation of ERK1/2 in a manner sensitive to the
inhibition of the PDGFRb kinase [5]. Therefore, we
initiated our study by examining whether dopamine and
the PDGFRb ligand, PDGF-BB, activate the PDGFRb in
a similar manner. The commercially available antibodies
do not reliably detect the phosphorylation of the endo-
genously expressed hamster PDGFRb in the CHO/
DRD4 cells; therefore, to facilitate the detection of
PDGFRb phosphorylation at the different tyrosine phos-
phorylation sites, the human FLAG-tagged PDGFRb was
stably transfected into the CHO/DRD4 cells to create
CHO/DRD4-PR cells [14]. In CHO/DRD4-PR cells, the
DRD4-mediated PDGFRb and ERK1/2 phosphorylation
was inhibited by pre-treatment with the PDGFRb kinase
inhibitors, tyrphostin A9, AG1295, and AG1296 in a
similar manner as in the CHO/DRD4 cells (data not
shown).
Using the CHO/DRD4-PR cells, we compared the pat-
tern of PDGFRb phosphorylation after stimulation with
either 1 μM dopamine or 10 ng/mL PDGF-BB. As
s h o w ni nF i g u r e1 A ,t h el e v e lo ft o t a lt y r o s i n ep h o s -
phorylation of PDGFRb w a sl e s sf o l l o w i n gd o p a m i n e
treatment compared to PDGF-BB stimulation.
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eral SH2 domain-binding sites [Grb2 (Tyr716), PI3-
kinase (Tyr740/751) and PLC-g (Tyr1021)] of the
PDGFRb also showed stronger phosphorylation in
response to PDGF-BB compared to dopamine. Interest-
ingly, Tyr857, the major site of tyrosine phosphorylation
in PDGF-stimulated cells [21], was phosphorylated only
by PDGF-BB, but not dopamine (Figure 1A). The
absence of phosphorylation of this site may explain the
overall lower tyrosine phosphorylation of PDGFRb
caused by DRD4 stimulation.
Since the receptor kinase activity is not enhanced
through Tyr857 phosphorylation, the dopamine-induced
PDGFRb phosphorylation may be a result of the basal
kinase activity of the PDGFRb. The phospho-specific
antibody against Tyr1021 of the PDGFRb does recognize
the endogenously expressed hamster receptor; therefore,
we used this antibody to measure PDGFRb phosphoryla-
tion in CHO/DRD4 cells. As shown in Figure 1B, the
dopamine-induced tyrosine phosphorylation of PDGFRb
(Tyr1021) and the phosphorylation of ERK1/2 were
reduced by the PDGFRb kinase inhibitor AG1295.
T op r o v i d ed i r e c te v i d e n c ef o rar o l eo ft h eP D G F R b
in dopamine-stimulated ERK1/2 activation, we used
siRNA to suppress endogenous PDGFRb expression in
the CHO/DRD4 cells. In these cells, the PDGFRb exists
as two isoforms that can be detected by western blot-
ting: a maturely glycosylated receptor (180 kDa) and a
140 kDa, immaturely glycosylated, isoform [22,23]. In
our siRNA experiments, two separate dsRNA constructs
were used that showed a similar efficacy in reducing the
levels of maturely glycosylated PDGFRb (Figure 2A, B).
Figure 1 Phosphorylation of PDGFRb following DRD4 versus PDGF-BB stimulation. (A) Differential pattern of phosphorylation of the
PDGFRb elicited by PDGF-BB and DRD4 in CHO-K1 cells overexpressing DRD4 and FLAG-PDGFRb (CHO/DRD4-PR). (B) Time course of dopamine-
stimulated phosphorylation of endogenous PDGFRb and ERK1/2 in CHO/DRD4 in the presence or absence of AG1295 (10 μM). AG1295 was pre-
incubated with the cells for 1 h before agonist stimulation. (A-B) CHO/DRD4 or CHO/DRD4-PR was stimulated for 5 min, or for the time
indicated, with 10 ng/mL PDGF-BB or 1 μM dopamine. IP: immunoprecipitation; IB: immunoblot.
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form of PDGFRb was not effectively suppressed by
either siRNA approach. This band was still present in
our western blots when different PDGFRb antibodies
were used; additionally, a similar band was seen in
CHO/DRD4 cells transfected with FLAG epitope-tagged
PDGFRb (not shown), suggesting that this band repre-
sents a genuine isoform of PDGFRb.U p o ns i R N A -
mediated PDGFRb suppression, both dopamine (1 μM)
and PDGF-BB (10 ng/ml) treatment showed
Figure 2 PDGFRb siRNAs inhibit dopamine-mediated ERK1/2 activation. (A) 100 nM of double-stranded PDGFRb interference RNA (PDGFRb
silencer 1) or (B) 30 nM of double-stranded PDGFRb RNA (PDGFRb silencer 2) was transfected into the CHO/DRD4 cells. Cells were harvested at
72 h post transfection and PDGFRb expression was determined. For phospho-ERK1/2 expression (Thr202/Tyr204), cells were serum-starved
overnight (beginning at 48 h post-transfection) and subsequently treated with dopamine (1 bM) or PDGF-BB (10 ng/ml).
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tion compared to controls. A scrambled dsRNA did not
cause a decrease in PDGFRb expression (data not
shown), nor did it suppress ERK1/2 phosphorylation
(Figure 2A). These results demonstrate that PDGFRb
may be involved in DRD4-mediated ERK1/2 activation.
We then tried to examine the existence of PDGFRb-
specific ligand PDGF-B in the CHO-K1 cells. Previous
reports have shown that HB-EGF acts as a paracrine
factor in the GPCR-induced transactivation of EGFR
[24]. In addition, the PDGF-C and PDGF-D isoforms
are secreted as latent pro-peptides and can be cleaved to
their active states by extracellular proteases. This has led
to the speculation that either PDGF or a PDGF-like
ligand may mediate GPCR-induced PDGFRb transacti-
vation via a similar metalloproteinase-dependent pro-
cess. Thus, to explore any involvement of a paracrine
factor in DRD4-mediated PDGFRb transactivation, we
examined the endogenous expression of PDGFs and
PDGFRs in CHO-K1 cells using RT-PCR. As a positive
control, the primers were tested in hamster and mouse
cardiac tissues and were found to produce PCR pro-
ducts of the expected size (Figure 3Ai, iv, vi). Using the
same primers, CHO-K1 cells were found to express
PDGF-A and PDGF-C; however, no PDGF-B mRNA
was detected in these cells (Figure 3Aii). The PCR pro-
ducts obtained for PDGF-D, using two independent pri-
mer sets, did not correspond to that obtained with the
control hamster tissues (Figure 3Aiii, and data not
shown), suggesting that the band from the CHO-K1
cells was due to non-specific amplification. Sequence
analysis confirmed that the observed PDGF-D band was
due to non-specific amplification of the presenilin gene.
Therefore, CHO-K1 cells express only PDGF-A and
PDGF-C, and not PDGF-B or PDGF-D. PDGF-A and
PDGF-C are PDGFRa-specific ligands and have been
shown to bind PDGFRb only when PDGFRa is also pre-
s e n t[ 1 , 2 5 ] .U s i n gR T - P C R ,i tw a sf o u n dt h a tC H O - K 1
cells do not express PDGFRa, but do express PDGFRb
(Figure 3Av). These results suggest that in CHO-K1
cells, the transactivation of PDGFRb by DRD4 stimula-
tion is unlikely to be produced via a paracrine mechan-
ism by known PDGFRb ligands.
The metalloproteinase inhibitor GM6001 is known to
block LPA-mediated Shc phosphorylation in COS-7
cells [12]. Thus, we tested the potential role of metallo-
proteinases in DRD4-mediated ERK1/2 phosphorylation.
As shown in Figure 3A, both GM6001 and the mutant
of diphtheria toxin CRM197, which binds HB-EGF and
inhibits ectodomain shedding [12], reduced the LPA-
induced Shc phosphorylation in COS-7 cells. However,
they were ineffective in blocking DRD4-mediated ERK1/
2 phosphorylation in CHO/DRD4 cells (Figure 3B).
T h e s er e s u l t ss u g g e s tt h e r ei sl i t t l eo rn or o l eo f
metalloproteinases in DRD4-mediated ERK1/2
phosphorylation.
Although the RT-PCR experiments showed the
absence of PDGFRb-specific ligands, we sought to
exclude the possible activation of PDGFRb by a yet
undiscovered ligand. To identify any potential PDGFRb
ligand released upon dopamine stimulation, a co-culture
strategy [12,26] in which two different populations of
cells were cultured together was employed. We created
one population of CHO-K1 cells (CHO/PR), which sta-
bly expressed FLAG-tagged human PDGFRb,b u tn o t
DRD4. The CHO/DRD4 cell line described above was
used as our second population of cells. As expected,
when cultured alone, the CHO/PR cells showed ERK1/2
activation in response to PDGF-BB, but not to dopa-
mine, while the CHO/DRD4 cells responded to both
dopamine and PDGF-BB (Figure 3C, left hand side)
when cultured alone. Interestingly, when the two cell
populations were co-cultured at a high density in a 1:1
ratio, dopamine-induced ERK1/2 phosphorylation was
approximately half as that observed with the CHO/
DRD4 monoculture, unlike the PDGF-BB-mediated
ERK1/2 response, which was similar in the monocul-
tures and co-culture. We speculated that the reduced
dopamine-mediated ERK1/2 phosphorylation in the co-
culture is due to the decrease of paracrine mediator, as
only half of the cells in this culture express DRD4.
Furthermore, immunoprecipitation of the FLAG-tagged
PDGFRb in the CHO/PR cells from the co-culture, fol-
lowed by immunoblotting of phospho-tyrosine residues
revealed an enhanced phosphorylation in response to
PDGF-BB, but not dopamine (Figure 3C, right hand
side). This further suggests that a paracrine mediator of
PDGFRb activation is not released by the CHO/DRD4
cells within the co-culture, in response to dopamine.
Taken together, our results from the co-culture and
metalloproteinase inhibitor studies suggest that the
mechanism of DRD4-mediated transactivation of
PDGFRb does not involve a paracrine factor or it
involves a paracrine factor that does not induce
transactivation.
The observations that PDGF is not involved in DRD4-
mediated PDGFRb transactivation led us to speculate
that the DRD4-ERK1/2 pathway is mechanistically dif-
ferent from the growth factor-activated ERK1/2 path-
way, although both pathways utilize PDGFRb.F i r s t ,w e
explored the role of PDGFRb cross-phosphorylation in
DRD4- or PDGF-BB-induced ERK1/2 and PDGFRb
phosphorylation. A mouse PDGFRb mutant with a dele-
tion in the intracellular domain has previously been
shown to inhibit PDGF-mediated signaling due to its
ability to heterodimerize with the full-length receptor,
thereby blocking the formation of functional PDGFRb
dimers and consequently receptor cross-phosphorylation
Chi et al. Molecular Brain 2010, 3:22
http://www.molecularbrain.com/content/3/1/22
Page 6 of 12[15]. A similar deletion mutant (see Methods) was cre-
ated for the human PDGFRb (C-truncPDGFRb)a n d
transfected into CHO/DRD4-PR. The cells were lysed
and the phosphorylation of ERK1/2 was examined by
western blotting with phospho-ERK1/2 antibody (E10).
The degree of phosphorylation was quantified using
ImageQuant and expressed as percentage of maximal
response. The EC50 values were determined by fitting to
a sigmoidal dose-response equation in GraphPad Prism.
The log EC50 values for dopamine were: CHO/DRD4,
-8.56 ± 0.11 (n = 4); CHO/DRD4-PR, -8.44 ± 0.23 (n =
3). The log EC50 values for PDGF-BB were: CHO/
DRD4, -10.13 ± 0.16 (n = 4); CHO/DRD4-PR, -10.41 ±
0.15 (n = 3). Assays were carried out at or near EC50
concentrations of dopamine and PDGF-BB so that a
false negative inhibition due to over-stimulation of the
signaling pathway could be avoided (Figure 4A).
The effect of C-truncPDGFRb was examined by wes-
tern blotting with general phospho-tyrosine or site-speci-
fic phospho-antibodies as indicated. To prevent the effect
from being masked by signal amplification, the cells were
stimulated with submaximal concentrations of either
PDGF-BB or dopamine. Immunoprecipitation with anti-
FLAG antibody was performed prior to blotting with
general phospho-tyrosine antibodies. Relative to the lacZ
control plasmid, transfection of C-truncPDGFRb reduced
Figure 3 Absence of a paracrine mediator in DRD4-mediated PDGFRb transactivation. (A) mRNA expression of known PDGF ligands and
the a and b subtypes of PDGFR. RT-PCR was performed on total RNA extracted from CHO-K1 cells or as controls, on total RNA taken from the
cardiac tissues of hamster or C57/black mouse. The primers were designed with the primer3 software to target sequences that are conserved
between mouse and human and to yield PCR products of sizes between 200 to 300 bp. Expression of PDGF-A, PDGF-C and PDGFRb were
detected in CHO-K1 cells, with PDGF-D being a non-specific band. (B) CHO/DRD4 or COS-7 cells were treated with the diphtheria toxin mutant
CRM197 (10 μg/mL) or the metalloproteinase inhibitor GM6001 (5 μM) for 30 min. The cells were subsequently stimulated with 1 μM dopamine
(CHO/DRD4) or 10 μM LPA (COS-7), and lysates were taken for western blotting with phospho-ERK1/2 (CHO/DRD4) or phospho-Shc (COS-7). The
inhibitors had no effect on dopamine-stimulated ERK1/2 phosphorylation. (C) CHO/DRD4 and CHO-K1 cells stably expressing FLAG-PDGFRb
(CHO/PR) were cultured separately or together at 90% confluency in a ratio of 1:1. The cells were stimulated with 10 ng/mL PDGF-BB or 1 μM
dopamine as indicated. Lysates were collected to probe with phospho-ERK1/2 antibody (left blot) or taken for immunoprecipitation with anti-
FLAG antibody and immunoblotted with phosphotyrosine antibody (pTyr) (right blot). IP: immunoprecipitation; IB: immunoblot.
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as receptor phosphorylation in response to both PDGF-
BB and dopamine (Figure 4B). A corresponding reduc-
tion was also observed at two of the SH2 domain-binding
sites. The phosphorylation of the Grb2 site (Tyr716) and
the major PLC-g binding site (Tyr1021) in unstimulated
CHO/DRD4-PR and those stimulated by either PDGF-
BB or DRD4 activation was reduced by the C-
truncPDGFRb to near basal levels (Figure 4B). Similar to
its effect on PDGF-stimulated PDGFRb tyrosine
Figure 4 Cross-tyrosine phosphorylation of PDGFRb is not required for DRD4-mediated ERK1/2 activation. (A) Dose-response of DRD4-
and PDGF-BB-mediated ERK1/2 phosphorylation. CHO/DRD4 (black square) or CHO/DRD4-PR (black triangle) cells were treated with different
concentrations of dopamine or PDGF-BB for 5 min. (B) Effect of C-truncPDGFRb on the phosphorylation of full-length PDGFRb and ERK1/2 in
CHO/DRD4-PR cells mediated by PDGF-BB and DRD4. CHO/DRD4-PR cells were transfected with C-truncPDGFRb, or with lacZ as a control. IP:
immunoprecipitation; IB: immunoblot. (C) DRD4-mediated phosphorylation of ERK1/2 in CHO/DRD4 was not blocked by C-truncPDGFRb. (D)
Requirement for PDGFRb in the DRD4-mediated phosphorylation of ERK1/2 in C-truncPDGFRb-transfected cells. Upper blot shows the
phosphorylation of ERK1/2 in lacZ-transfected and C-truncPDGFRb-transfected CHO/DRD4 cells that have been pre-treated with DMSO or 1 μM
tyrphostin A9 prior to stimulation with dopamine. (B-D) The blots were stripped and re-probed with antibodies for PDGFRb or ERK1/2 to verify
that the total protein did not vary between lanes. In (C) and (D), the bar graphs show densitometric measurements of the phosphorylation
signal from the respective experiments. The results are expressed as percentages relative to lacZ control and indicated as mean ± SEM. The
number of experiments is indicated in parentheses.
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ERK1/2 phosphorylation in response to PDGF-BB. In
contrast, the DRD4-mediated ERK1/2 phosphorylation
was unaffected by expression of C-truncPDGFRb.T h e s e
results suggest that unlike PDGF-mediated signaling,
DRD4-induced ERK1/2 phosphorylation is not contin-
gent on PDGFRb cross-phosphorylation.
We further confirmed that the differential effect of the
C-truncPDGFRb on PDGF- and DRD4-mediated signal-
ing was not due to signal amplification caused by our
overexpression of recombinant PDGFRb by examining
ERK1/2 phosphorylation in CHO/DRD4 cells, which
express the PDGFRb endogenously. Consistent with
our observations in CHO/DRD4-PR cells, the C-
truncPDGFRb blocked PDGF-BB-mediated ERK1/2
phosphorylation in CHO/DRD4 cells (Figure 4C). In
contrast, C-truncPDGFRb did not inhibit the ERK1/2
phosphorylation that was stimulated by submaximal
concentrations of dopamine. To ascertain that the lack
of effect of C-truncPDGFRb on DRD4-mediated ERK1/2
phosphorylation is not due to overexpression of
PDGFRb, the experiment was also performed in CHO/
DRD4. The p values for the 0.3 ng/mL and 1 ng/mL
PDGF-BB-treated groups are 0.02 and 0.01, respectively,
according to the paired t-test. Moreover, in the presence
of C-truncPDGFRb, the DRD4-mediated ERK1/2 phos-
phorylation remained sensitive to PDGFR kinase inhibi-
tion, showing that basal kinase activity of PDGFRb is
still required for DRD4-mediated PDGFRb transactiva-
tion (Figure 4D).
The lack of the need for PDGFRb cross-phosphoryla-
tion in DRD4-mediated ERK1/2 activation suggests that
PDGFRb dimerization is also not required. We investi-
gated the need for receptor dimerization, by utilizing a
glutathione S-transferase fusion protein to inhibit the
formation of PDGFRb dimers. Previous reports have
shown that a glutathione S-transferase-PDGFRa-Ig4
domain fusion protein (GST-Ig4a)p e r t u r b sP D G F R a
dimerization [18]. The extracellular Ig4 domain of
PDGFRb is known to provide the interface for subunit-
subunit interaction without playing a role in ligand
binding [17,18,27,28]. Therefore, to specifically block
PDGFRb dimerization, a glutathione S-transferase-
PDGFRb-Ig4 (GST-Ig4b)f u s i o np r o t e i nw a sc o n -
structed. Pre-incubation of CHO/DRD4-PR cells with
GST alone had little effect on the ability of dopamine or
PDGF-BB to elicit an ERK1/2 response (Figure 5). How-
ever, incubation with GST-Ig4b prevented PDGF-BB-sti-
mulated ERK1/2 phosphorylation. Conversely, blocking
PDGFRb dimerization with GST-Ig4b did not affect
DRD4-mediated ERK1/2 phosphorylation. These results
suggest that DRD4 can activate ERK1/2 by utilizing the
PDGFRb in a way that does not require receptor
dimerization.
Previous data from our laboratory [5] suggested the
involvement of PI3-kinase in the DRD4-mediated activa-
tion of PDGFRb. In order to determine whether PI3-
kinase plays a role in the DRD4-stimulated activation of
ERK1/2 following the block of PDGFRb dimerization,
CHO/DRD4-PR cells were pre-treated with 100 nM
wortmannin for one hour prior to incubation with GST
or GST-Ig4b and subsequent treatment with dopamine
or PDGF-BB. Wortmannin inhibited the DRD4-
mediated ERK1/2 activation observed following PDGFRb
dimerization block with GST-Ig4b,s u g g e s t i n gar o l ef o r
PI3-kinase in this pathway.
Discussion
The present study has demonstrated a novel mechanism
for PDGFRb signaling, in which DRD4-mediated trans-
activation of PDGFRb and the subsequent activation of
ERK1/2 does not involve mechanisms that are charac-
teristic of RTK activation. This new scheme breaks away
from the prototypical model, where GPCR-mediated
RTK transactivation is ligand-dependent, and so occurs
similarly to classical RTK signaling involving receptor
dimerization and cross-phosphorylation.
The use of RT-PCR failed to detect any of the known
endogenous PDGFRb ligands within our CHO-K1 cells
(Figure 3A). Additionally, inhibition of metalloprotei-
nases failed to suppress DRD4-mediated ERK1/2 activa-
tion (Figure 3B), and no evidence of a paracrine
mediator was found in DRD4-PDGFRb transactivation,
as demonstrated by our co-culture experiments (Figure
3C). Furthermore, phosphorylation of Tyr857 of the
PDGFRb, a hallmark of ligand-induced activation, was
not seen after dopamine treatment (Figure 1A). These
lines of evidence argue strongly against the involvement
of a paracrine-mediated event in the DRD4-PDGFRb-
ERK1/2 pathway.
Furthermore, dimerization and subsequent cross-phos-
phorylation of PDGFR are also not required for DRD4-
mediated transactivation. DRD4 stimulation led to
increased general tyrosine phosphorylation of the
PDGFRb (Figure 1). However, inhibition of the PDGFRb
cross-tyrosine phosphorylation with the C-truncPDGFRb
did not affect dopamine-induced ERK1/2 activation (Fig-
ure 4). Similarly, blocking PDGFRb dimerization with a
GST-Ig4b fusion protein did not diminish DRD4-
mediated ERK1/2 phosphorylation (Figure 5). Both lines
of evidence point to a mechanism that does not require
either dimerization or cross-phosphorylation which are
hallmarks of RTK activation. Interestingly, wortmannin
inhibits the DRD4-mediated ERK1/2 activation observed
following PDGFRb dimerization block with GST-Ig4b
(Figure 5B), suggesting a role for PI3-kinase in this
pathway.
Chi et al. Molecular Brain 2010, 3:22
http://www.molecularbrain.com/content/3/1/22
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phosphorylation that follows DRD4 stimulation appears
to be unrelated to the ERK1/2 signaling pathway. It is
not clear how the transactivated PDGFRb mediates sig-
naling in the absence of enhanced tyrosine
phosphorylation. The sensitivity of DRD4-mediated
ERK1/2 signaling to PDGFRb kinase inhibitors suggests
that a certain level of basal kinase activity is required.
An alternative explanation is that through a tyrosine
phosphorylation-independent conformational change,
Figure 5 Blocking PDGFRb dimerization inhibits ERK1/2 activation in PDGF-BB-treated, but not in dopamine-stimulated CHO-K1 cells.
(A) CHO/DRD4-PR cells were pretreated with 4 μg/mL of either GST or GST-PDGFRb immunoglobulin domain 4 (GST-Ig4b) fusion proteins for 20
min at 37°C to prevent PDGFRb dimerization and were then stimulated with 1 μM dopamine or 10 ng/mL PDGF-BB for 5 min. Lysates were
taken for western blotting with phospho-ERK1/2 antibody (upper blot). The same blot was stripped and reprobed for total PDGFRb to
demonstrate equal loading of all lanes (lower blot). (B) Pre-treatment with 100 nM wortmannin for one hour abolished the dopamine-mediated
ERK1/2 signal following PDGFRb dimerization block with GST-Ig4b. The same blot was stripped and reprobed for b-tubulin to demonstrate equal
loading of all lanes (lower blot). The bar graphs show the densitometric measurement of the relative signals from phospho-ERK1/2 over two to
four experiments, and the quantities were given as mean ± SEM.
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PDGFRb-ERK1/2 signaling. In fact, growth factor-acti-
vated PDGFRb is known to undergo conformational
changes that can be either enhanced by mutations that
result in constitutive activity [29] or those that suppress
kinase activity [30]. Interestingly, several studies have
revealed a mechanistic intricacy of PDGFRb signaling
beyond a simple relationship of dimerization and cross-
phosphorylation. There is evidence that PDGF-activated
mitogenic responses and receptor tyrosine phosphoryla-
tion do not always correlate [31-33].
T h ep r e s e n ts t u d ys h o w st h a tu n l i k et h ep r o t o t y p i c a l
mechanism underlying GPCR-RTK transactivation,
DRD4-PDGFRb-ERK1/2 signaling does not involve a para-
crine component, nor does it require PDGFRb cross-phos-
phorylation and dimerization. This suggests that PDGFRb
can act as a monomeric scaffold to transmit DRD4-
mediated signals, in a tyrosine phosphorylation-indepen-
dent manner. We have recently demonstrated that DRD4
is able to transactivate immaturely glycosylated PDGFRb,
which is intracellularly localized [34]. These findings pre-
clude the involvement of an extracellular ligand-mediated
mechanism of PDGFRb activation, and would allow DRD4
to remain engaged in the ERK1/2 signaling pathway,
despite desensitization of plasma membrane-expressed
PDGFRb. The actual mechanism of how DRD4 stimula-
tion induces PDGFRb transactivation is still unknown, but
we speculate that it involves a diffusable factor, such as
PI3-kinase, that would be able to act on a monomeric,
intracellularly localized PDGFRb. The DRD4-PDGFRb-
ERK1/2 pathway is distinct from other known forms of
transactivation, and so represents a novel system that
already has implications in the regulation of downstream
effectors such as the NMDA receptor.
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